This study supports genotyping of TERT promoter and IDH1/2 in gliomas as a rapid economical test requiring little tumoral DNA that could help inform clinicians as to the predicted OS of these tumors that may differ from their predicted outcomes based on conventional histology alone. Here, IDH1 is linked to central nervous system cancer.